Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
18.42
+0.81 (4.60%)
At close: Jun 9, 2026, 4:00 PM EDT
18.06
-0.36 (-1.95%)
After-hours: Jun 9, 2026, 4:21 PM EDT
Zenas BioPharma Revenue
In the year 2025, Zenas BioPharma had annual revenue of $10.00M with 100.00% growth.
Revenue (ttm)
$10.00M
Revenue Growth
+100.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
167
Market Cap
1.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | 5.00M | 100.00% |
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 7 days ago - Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine - GlobeNewsWire
- 7 days ago - Zenas BioPharma Slides: Corporate presentation - Filings
- 12 days ago - Zenas BioPharma submits BLA to FDA for obexelimab - TheFly
- 12 days ago - Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - GlobeNewsWire
- 21 days ago - Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - GlobeNewsWire
- 22 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Zenas BioPharma price target raised to $22 from $21 at Morgan Stanley - TheFly
- 26 days ago - Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma - TheFly